We have located links that may give you full text access.
Nivolumab Gets FDA Nod for Bladder Cancer.
Cancer Discovery 2017 April
The FDA has granted accelerated approval to nivolumab for patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed on platinum chemotherapy. This is the second PD-1 - targeting agent in less than a year to get the agency's nod for bladder cancer.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app